CathWorks

CathWorks is a medical technology company that focuses on improving the diagnosis and treatment of coronary artery disease (CAD) through advanced computational science. Their primary innovation, the CathWorks FFRangio® System, transforms standard coronary angiograms into detailed physiological assessments without the need for invasive pressure wires or drug stimulation. This system utilizes artificial intelligence and computational modeling to deliver real-time fractional flow reserve (FFR) measurements, enabling physicians to make informed decisions regarding CAD therapy. The FFRangio System enhances coronary angiography by providing objective, physiology-based data. It features color-coded 3D renderings of blood flow, real-time FFR values, and integrated tools for lesion sizing and impact analysis. The system is designed for interventional cardiologists and healthcare systems, aiming to improve the efficiency of CAD diagnosis and treatment. CathWorks has received multiple regulatory approvals and continues to expand its clinical evidence through global studies, demonstrating its commitment to enhancing patient outcomes and optimizing healthcare resources.

• Employees 81
• Founded 2013
• Annual Revenue $10500000
• Total Funding $151793924